EGFR and non-small cell lung carcinoma: NSCLC patients frequently harbour activating mutations in the epidermal growth factor receptor (EGFR) gene, particularly in the first four exons (exons 18–21) of the EGFR tyrosine kinase domain, which is strikingly high in East Asian populations.1